重编程
生物
癌症的体细胞进化
髓系白血病
白血病
癌症研究
细胞生物学
细胞
免疫学
遗传学
基因
作者
Sunil K. Joshi,Tamilla Nechiporuk,Daniel Bottomly,Paul Piehowski,Julie A. Reisz,Janét Pittsenbarger,Andy Kaempf,Sara J.C. Gosline,Yi-Ting Wang,Joshua Hansen,Marina Gritsenko,Chelsea Hutchinson,Karl Weitz,Jamie Moon,Francesca Cendali,Thomas Fillmore,Chia‐Feng Tsai,Athena Schepmoes,Tujin Shi,Osama A. Arshad
出处
期刊:Cancer Cell
[Cell Press]
日期:2021-06-24
卷期号:39 (7): 999-1014.e8
被引量:107
标识
DOI:10.1016/j.ccell.2021.06.003
摘要
Our study details the stepwise evolution of gilteritinib resistance in FLT3-mutated acute myeloid leukemia (AML). Early resistance is mediated by the bone marrow microenvironment, which protects residual leukemia cells. Over time, leukemia cells evolve intrinsic mechanisms of resistance, or late resistance. We mechanistically define both early and late resistance by integrating whole-exome sequencing, CRISPR-Cas9, metabolomics, proteomics, and pharmacologic approaches. Early resistant cells undergo metabolic reprogramming, grow more slowly, and are dependent upon Aurora kinase B (AURKB). Late resistant cells are characterized by expansion of pre-existing NRAS mutant subclones and continued metabolic reprogramming. Our model closely mirrors the timing and mutations of AML patients treated with gilteritinib. Pharmacological inhibition of AURKB resensitizes both early resistant cell cultures and primary leukemia cells from gilteritinib-treated AML patients. These findings support a combinatorial strategy to target early resistant AML cells with AURKB inhibitors and gilteritinib before the expansion of pre-existing resistance mutations occurs.
科研通智能强力驱动
Strongly Powered by AbleSci AI